Phaseline

Companies › QBiotics Group

QBiotics Group: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tigilanol Tiglate
Protein kinase C (PKC) activator
–Phase 2Head and Neck Cancer; Soft Tissue SarcomaJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05608876Tigilanol TiglatePhase 2Head and Neck CancerOncologyJul 2025
NCT05755113Tigilanol TiglatePhase 2Soft Tissue SarcomaOncologyJan 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.